Rani Therapeutics Holdings (RANI) Operating Margin (2020 - 2026)
Rani Therapeutics Holdings' (RANI) quarterly Operating Margin came in at 488.23% in Q1 2026, up 649607.0% year-on-year from N/an in Q1 2025, and up 16.43% quarter-over-quarter from 584.19% in Q4 2025.
Rani Therapeutics Holdings (RANI) Operating Margin (2020 - 2026) Analysis & Trends
Rani Therapeutics Holdings' Operating Margin history runs 5 years deep, the most recent figure standing at 488.23% for Q1 2026.
- On a quarterly basis, Operating Margin rose 649607.0% year-over-year to 488.23% in Q1 2026; TTM through Mar 2026 was 1092.96%, a 318154.0% increase from a year earlier, with the FY2025 full-year figure at 2345.99%, up 284020.0% from the prior year.
- Operating Margin grew to 488.23% in Q1 2026 per RANI's latest filing, from 584.19% in the prior quarter.
- Across five years, Operating Margin topped out at 488.23% in Q1 2026 and bottomed at 6984.3% in Q1 2025.
- The 3-year median for Operating Margin is 1019.62% (2025), against an average of 2377.95%.
- Across the five-year window, Operating Margin soared 87087 bps in 2025 and soared 649607 bps in 2026, its largest moves.
- Year by year, Operating Margin stood at 1455.06% in 2024, then surged by 60 bps to 584.19% in 2025, then grew by 16 bps to 488.23% in 2026.
- Per Business Quant, the three latest RANI Operating Margin figures stand at 488.23% (Q1 2026), 584.19% (Q4 2025), and 6984.3% (Q1 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | - |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.62 Bn | 466.83 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.75 Bn | 50.57 Bn | 1.41 Bn | 31.68% |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 23.02% |
| 10 | Rani Therapeutics Holdings | 144.57 Mn | 144.57 Mn | - | -488.23% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -488.23% |
| Dec 31, 2025 | -584.19% |
| Mar 31, 2025 | -6,984.30% |
| Dec 31, 2024 | -1,455.06% |
| Jun 30, 2021 | -268.13% |
| Mar 31, 2021 | -687.57% |
| Dec 31, 2020 | -2,354.29% |
| Sep 30, 2020 | -2,617.59% |
| Jun 30, 2020 | -5,650.00% |